Kenvue Inc. (NYSE:KVUE) Given Consensus Rating of “Hold” by Brokerages

Kenvue Inc. (NYSE:KVUE) has earned a consensus rating of “Hold” from the fourteen analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $23.09.

A number of research analysts have commented on the company. Citigroup reiterated a “neutral” rating and issued a $21.00 price objective on shares of Kenvue in a research report on Tuesday, May 28th. HSBC raised their price target on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Wednesday, May 8th. Sanford C. Bernstein initiated coverage on Kenvue in a research report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target on the stock. Finally, William Blair initiated coverage on Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating on the stock.

Institutional Trading of Kenvue

Institutional investors have recently modified their holdings of the company. Stephens Inc. AR lifted its holdings in shares of Kenvue by 86.1% in the fourth quarter. Stephens Inc. AR now owns 57,694 shares of the company’s stock valued at $1,242,000 after purchasing an additional 26,700 shares in the last quarter. Stifel Financial Corp raised its holdings in Kenvue by 60.4% during the fourth quarter. Stifel Financial Corp now owns 745,064 shares of the company’s stock worth $16,041,000 after acquiring an additional 280,591 shares in the last quarter. Raleigh Capital Management Inc. raised its holdings in Kenvue by 93,834.8% during the fourth quarter. Raleigh Capital Management Inc. now owns 43,210 shares of the company’s stock worth $930,000 after acquiring an additional 43,164 shares in the last quarter. Fifth Third Bancorp raised its holdings in Kenvue by 35.3% during the fourth quarter. Fifth Third Bancorp now owns 277,580 shares of the company’s stock worth $5,976,000 after acquiring an additional 72,435 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Kenvue by 2.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 1,598,567 shares of the company’s stock worth $34,417,000 after acquiring an additional 40,995 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Down 0.2 %

Shares of KVUE opened at $18.22 on Wednesday. The firm has a market capitalization of $34.89 billion, a price-to-earnings ratio of 23.36, a PEG ratio of 1.93 and a beta of 1.40. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.99. The business’s fifty day moving average price is $19.08 and its two-hundred day moving average price is $19.85. Kenvue has a 52 week low of $17.75 and a 52 week high of $25.61.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. The firm had revenue of $2.89 billion for the quarter, compared to analyst estimates of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The firm’s revenue was down 24.9% compared to the same quarter last year. On average, analysts predict that Kenvue will post 1.17 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 4.39%. The ex-dividend date was Tuesday, May 7th. Kenvue’s dividend payout ratio is 102.56%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.